COVID-19: Vaccines and Therapeutics
The Food and Drug Administration authorized administering the monoclonal antibodies casirivimab and imdevimab together to certain COVID-19 outpatients at risk for severe disease.
Drug maker AstraZeneca said it will seek an emergency use authorization for its AZD1222 vaccine candidate for SARS-CoV-2 following positive high-level results from an interim analysis of ongoing clinical trials.
The Food and Drug Administration authorized the emergency use of baricitinib in combination with remdesivir to treat suspected or laboratory confirmed COVID-19 in certain hospitalized patients requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.
Pfizer Inc. announced it will request emergency use authorization from the Food and Drug Administration for its BNT162b2 mRNA vaccine candidate against SARS-CoV-2.
The principals behind the federal Operation Warp Speed initiative expressed optimism that the Food and Drug Administration could soon authorize two safe and highly effective COVID-19 vaccines.
This snapshot provides an overview of three treatments including Veklury (remdesivir), Eli Lilly’s bamlanivimab, and Regeneron’s antibody cocktail.
An AHA Member Call on Allocation and Distribution of Operation Warp Speed (OWS) Therapeutics with Nancy Foster and John Redd, MD, CMO, ASPR, including remdesivir and monoclonal antibody (MAB) therapeutics like bamlanivimab through the Emergency Use Authorization (EUA).
Moderna Inc. announced that its mRNA-1273 vaccine candidate against COVID-19 is 94.5% effective, according to early data.
As of Nov. 6, about 60% of the nation’s retail pharmacies have agreed to participate in a federal program to administer COVID-19 vaccines at no cost to patients once authorized or licensed by the Food and Drug Administration, the departments of Health and Human Services and Defense announced.
With the COVID-19 pandemic reaching the point in which vaccines against the coronavirus may soon be publicly available, the AHA is helping hospitals and health systems prepare for their arrival, while promoting public confidence in Food and Drug Administration-approved SARS-CoV-2 vaccines.